{
    "Clinical Trial ID": "NCT00305695",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I (Zoledroic Acid)",
        "  Beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9, and 15.",
        "  Laboratory Biomarker Analysis: Correlative studies",
        "  Zoledronic Acid: Given IV",
        "INTERVENTION 2: ",
        "  Arm II (Clinical Observation)",
        "  Patients are observed for 18 months after surgery."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Patients who have elected to undergo, or who have undergone (within 8 weeks) a surgical procedure that results (at minimum) in the absence of both ovaries",
        "  Patients enrolled in the screening arm of GOG-0199 who decide to undergo surgery are potentially eligible for GOG-0215",
        "  Baseline bone mass density (BMD) T-Score ? -1.5 (no more than 1.5 standard deviation below the mean value for young adults) on both the total lumbar spine (L1-L4 region, not individual bones) and bilateral hip",
        "  Patients who had/have at least 1 intact ovary at the time of surgery are eligible",
        "  No prior distant metastatic malignant disease within the past 5 years",
        "  Patients treated for stage M1 (any T, any N) diagnosis in the past 5 years are ineligible",
        "  Patients who achieved a complete response after treatment for rM0 (any T, any N) within the past 5 years are eligible",
        "  Premenopausal*",
        "  Last menstrual cycle occurred < 12 months prior to study enrollment",
        "  GOG performance status 0-2",
        "  Creatinine clearance > 60 mL/min",
        "  No clinical or radiological evidence of existing fracture of the lumbar spine or bilateral hip",
        "  No history of hip of spine fracture with low-intensity trauma or not associated with trauma",
        "  No uncontrolled seizure disorder associated with falls",
        "  No diseases that influence bone metabolism, including any of the following:",
        "  Paget?s disease",
        "  Osteogenesis imperfecta",
        "  Uncontrolled thyroid or parathyroid dysfunction within 12 months prior to study entry",
        "  No other nonmalignant systemic disease, including any of the following:",
        "  Uncontrolled infection",
        "  Uncontrolled type 2 diabetes mellitus",
        "  Cardiovascular, renal, hepatic, or lung disease that would prevent prolonged follow-up",
        "  History of thrombosis or thromboembolism allowed",
        "  No known HIV positivity",
        "  No known hypersensitivity to zoledronate or other bisphosphonates",
        "  No psychiatric, psychological, or other conditions that prevent fully informed consent",
        "  No other active malignancy except nonmelanoma skin cancer",
        "  No history of any medical condition that places the patient at risk for donating blood for research purposes (e.g., chronic infectious diseases, sever anemia, or hemophilia)",
        "  Not pregnant",
        "  Negative pregnancy test",
        "  No current active dental problems, including any of the following:",
        "  Infection of the teeth or jawbone (maxilla or mandible)",
        "  Dental or fixture trauma",
        "  Current or prior diagnosis of osteonecrosis of the jaw",
        "  Exposed bone in the mouth",
        "  Slow healing after dental procedures",
        "  No recent (within 6 weeks) or planned dental or jaw surgery (e.g., extraction or implants)",
        "  No prior treatment for osteoporosis",
        "  No adjuvant radiotherapy within the past 31 days",
        "  No chemotherapy within the past 30 days",
        "  No prior surgery to the hip or spine",
        "  No prior systemic sodium fluoride for > 3 months during the past 2 years",
        "  No more than 30 days use in the past 12 months and no concurrent tamoxifen, raloxifene, or any other selective estrogen-receptor modulator (SERM)",
        "  More than 12 months since prior and no concurrent endocrine therapy",
        "  Insulin and/or oral antidiabetic medications allowed",
        "  Thyroid hormone replacement allowed",
        "  More than 12 months since prior and no concurrent estrogen or hormone replacement therapy (estrogen plus progesterone or estrogen alone)",
        "  Prior or concurrent oral contraceptives allowed",
        "  Systemic (oral) hormone replacement therapy following surgery not allowed",
        "  Vaginal (non-systemic) estrogen allowed",
        "  More than 12 months since prior and no concurrent oral or IV bisphosphonate",
        "  More than 12 months since prior and no concurrent anabolic steroids or growth hormone",
        "  More than 12 months since prior and no concurrent systemic corticosteroids",
        "  Concurrent short term corticosteroid therapy (to prevent/treat chemotherapy-induced nausea/vomiting) allowed",
        "  More than 6 months since prior and no concurrent Tibolone",
        "  More than 2 weeks since prior and no concurrent drugs known to affect the skeleton (e.g., calcitonin, mithramycin, or gallium nitrate)",
        "  No concurrent chemotherapy or radiotherapy",
        "  No concurrent aromatase inhibitors",
        "  Concurrent enrollment on protocol GOG-0199 allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Bone Mineral Density of the Lumbar Spine as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan at 9 Months",
        "  To compare the effect of zoledronic acid administered every 6 months on bone loss associated with surgery (at a minimum, any surgical procedure that results in removal of both ovaries), as compared with observation alone. This is to be evaluated by measuring the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine, specifically L1-L4 dual energy X-ray absorptiometry (DEXA).",
        "  Time frame: 9 Months",
        "Results 1: ",
        "  Arm/Group Title: Arm I (Zoledroic Acid)",
        "  Arm/Group Description: Beginning 60-90 days after surgery, patients receive zoledronate IV over 15 minutes once in months 3, 9, and 15.",
        "  Laboratory Biomarker Analysis: Correlative studies",
        "  Zoledronic Acid: Given IV",
        "  Overall Number of Participants Analyzed: 51",
        "  Mean (Full Range)",
        "  Unit of Measure: g/cm2  -0.025        (-0.240 to 0.077)",
        "Results 2: ",
        "  Arm/Group Title: Arm II (Clinical Observation)",
        "  Arm/Group Description: Patients are observed for 18 months after surgery.",
        "  Overall Number of Participants Analyzed: 68",
        "  Mean (Full Range)",
        "  Unit of Measure: g/cm2  -0.086        (-0.308 to 0.067)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/80 (1.25%)",
        "  Gastritis * 1/80 (1.25%)",
        "Adverse Events 2:",
        "  Total: 0/78 (0.00%)",
        "  Gastritis * 0/78 (0.00%)"
    ]
}